These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 5851172)

  • 21. [Effect of prostaglandin E1 in chronic obliterative diseases of peripheral arteries].
    Zhang GS
    Zhonghua Wai Ke Za Zhi; 1988 Sep; 26(9):541-2, 573. PubMed ID: 3243146
    [No Abstract]   [Full Text] [Related]  

  • 22. [Medical therapy of obliterating arteriopathies].
    Schwarz D
    Minerva Med; 1969 Oct; 60(87):4335-44. PubMed ID: 4242895
    [No Abstract]   [Full Text] [Related]  

  • 23. [Clinical considerations and functional data on the use of the association of kallikrein and meso-inositol hexanicotinate in the therapy of obliterating arteriopathy].
    Blasi A; Licciardello M
    Clin Ter; 1966 Jul; 38(2):121-58. PubMed ID: 5990194
    [No Abstract]   [Full Text] [Related]  

  • 24. [Taurine in the therapy of obliterating arteriopathy of the lower extremities. I. Clinical results in various evolutive phases].
    Zanelli G; Ferrero S; Patrone P
    Minerva Cardioangiol; 1971 Nov; 19(11):605-15. PubMed ID: 5128422
    [No Abstract]   [Full Text] [Related]  

  • 25. Chronic venous insufficiency treated with hydroxyethylrutosides (HR).
    Sorensen AH; Hansen H
    Angiologica; 1970; 7(3):187-92. PubMed ID: 4913054
    [No Abstract]   [Full Text] [Related]  

  • 26. Prostacyclin in the therapy of peripheral arterial disease.
    Szczeklik A; Gryglewski RJ; Nizankowski R; Szczeklik J; Skawiński S; Głuszko P
    Adv Prostaglandin Thromboxane Res; 1980; 7():687-9. PubMed ID: 6989195
    [No Abstract]   [Full Text] [Related]  

  • 27. [Our experience in antalgic therapy of peripheral arteriopathies].
    Tufano R; Portolano F; Bimonte D
    Rass Int Clin Ter; 1971 Mar; 51(6):370-4. PubMed ID: 5553226
    [No Abstract]   [Full Text] [Related]  

  • 28. [Thrombolytic treatment of chronic arterial obstruction].
    Mazák J; Bláha M; Vodicková L; Pidrman V
    Vnitr Lek; 1974 Jul; 20(6):596-602. PubMed ID: 4844794
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of organic diseases of peripheral arteries with nicotinic acid derivatives].
    Liszewska D; Lukasik E
    Pol Tyg Lek; 1967 May; 22(21):794-6. PubMed ID: 6041002
    [No Abstract]   [Full Text] [Related]  

  • 30. [Prostacyclin therapy of peripheral artery disease].
    Kusaba A
    Kokyu To Junkan; 1985 Jul; 33(7):871-6. PubMed ID: 3903902
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of carbogaseous baths in the treatment of chronic peripheral obliterating arteriopathies].
    Brassai Z; Horváth E; Csögör I; Ferencz L; Benedek G; Szász B
    Rev Med Chir Soc Med Nat Iasi; 1974; 78(3):603-8. PubMed ID: 4453683
    [No Abstract]   [Full Text] [Related]  

  • 32. [Therapeutic properties of xanthine nicotinate in the treatment of obliterating arteriopathies].
    Tardito E; Azzolini A; De Cristofaro A; Papacharalambus D
    Minerva Cardioangiol; 1972; 20(7):369-89. PubMed ID: 5050745
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical and hemodynamic aspects induced by eledoisin. Plethysmographic study of variations of flow in some forms of obliterating arterial disease of the legs, during intra-arterial infusion of eledoisin].
    Chiampo L; La Greca G; Ferrari S; Novarini A
    Minerva Cardioangiol; 1965 Jul; 13(7):375-82. PubMed ID: 5838537
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of peripheral ischemizing arteriopathies with diisopropylammonium dichloroethanoate (Diedì), a drug with action prevalent on respiratory tissue metabolism].
    Maggi GC; Tartara A
    Minerva Cardioangiol; 1965 Jul; 13(7):382-3. PubMed ID: 5838538
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapy of peripheral obliterating arteriopathies with intra-arterial perfusions of dextran of low molecular weight and vasodilator agents].
    Buccellato C; Di Lorenzo GD
    Minerva Chir; 1967 Jun; 22(11):692-5. PubMed ID: 6050666
    [No Abstract]   [Full Text] [Related]  

  • 36. [Prostacyclin in treatment of peripheral vascular disease of lower extremities (author's transl)].
    Szczeklik A; Głusko P; Gryglewski R; Szczeklik J; Kostka-Trabka E; Grodzińska L; Nizanowski R; Dembińska-Kieć A; Skawiński S; Bieroń K; Billewicz O; Telesz E
    Przegl Lek; 1980; 37(9):659-62. PubMed ID: 6106960
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of a new alpha-blocking vasodilator agent (thymoxamine) in peripheral vascular disease.
    Kane SP
    Br J Surg; 1970 Dec; 57(12):921-6. PubMed ID: 4395088
    [No Abstract]   [Full Text] [Related]  

  • 38. [PATHOGENESIS AND ROENTGENOLOGICAL PICTURE OF CHRONIC OBLITERATING PROCESSES IN THE BLOOD VESSELS OF THE LOWER EXTREMITIES].
    SKATULA L
    Cesk Rentgenol; 1964 May; 18():151-60. PubMed ID: 14158979
    [No Abstract]   [Full Text] [Related]  

  • 39. Nursing care of the patient with chronic occlusive peripheral artery disease.
    Boozer M; Craven RF
    Cardiovasc Nurs; 1981; 17(4):13-7. PubMed ID: 6911062
    [No Abstract]   [Full Text] [Related]  

  • 40. Preliminary results in the treatment of peripheral arteriopathies with a new pharmacologic substance: I-(2"pyrimidyl)4 piperonyl piperazine (ET 495).
    Royer RJ
    Bibl Cardiol; 1969; 26():174-9. PubMed ID: 5402343
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.